Gossamer bio appoints bob smith as chief commercial officer

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced the appointment of bob smith as its chief commercial officer. “we are proud to welcome bob smith to the gossamer team and his 30 years of expertise at this critical time in our company's history,” said faheem hasnain, chairman, co-founder and ceo of gos.
GOSS Ratings Summary
GOSS Quant Ranking